Darren R. Flower
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Darren R. Flower has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Irini Doytchinova
Drug Design and Bioinformatics Lab, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria
7 shared publications - Pedro Antonio Reche
Department of Immunology, Ophthalmology and ENT, Faculty of Medicine, Complutense University of Madrid, Pza Ramon y Cajal s/n, 28040 Madrid, Spain
7 shared publications - Kamna Ramakrishnan
Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
4 shared publications - Derek Gatherer
Division of Biomedical & Life Sciences, Faculty of Health & Medicine, Lancaster University, Lancaster, UK
3 shared publications - Amit Kumar Chattopadhyay
National College of Ireland
2 shared publications - Atanas Patronov
School of Pharmacy, Medical University of Sofia, 2 Dunav st, Sofia, 1000, Bulgaria
2 shared publications
Latest Publications
- Open Access
- 1 January 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020 (1) , 7235742
West Nile Virus Vaccine Design by T Cell Epitope Selection: In Silico Analysis of Conservation, Functional Cross‐Reactivity with the Human Genome, and Population Coverage
West Nile Virus (WNV) causes a debilitating and life‐threatening neurological disease in humans. Since its emergence in Africa 50 years ago, new strains of WNV and an expanding geographical distribution have increased public health concerns. There are no licensed therapeutics against WNV, limiting effective infection control. Vaccines represent the most efficacious and efficient medical intervention known. Epitope‐based vaccines against WNV remain significantly underexploited. Here, we use a selection protocol to identify a set of conserved prevalidated immunogenic T cell epitopes comprising a putative WNV vaccine. Experimentally validated immunogenic WNV epitopes and WNV sequences were retrieved from the IEDB and West Nile Virus Variation Database. Clustering and multiple sequence alignment identified a smaller subset of representative sequences. Protein variability analysis identified evolutionarily conserved sequences, which were used to select a diverse set of immunogenic candidate T cell epitopes. Cross‐reactivity and human leukocyte antigen‐binding affinities were assessed to eliminate unsuitable epitope candidates. Population protection coverage (PPC) quantified individual epitopes and epitope combinations against the world population. 3 CD8+ T cell epitopes (ITYTDVLRY, TLARGFPFV, and SYHDRRWCF) and 1 CD4+ epitope (VTVNPFVSVATANAKVLI) were selected as a putative WNV vaccine, with an estimated PPC of 97.14%.
- 1 January 2020
- Published by Wiley in Journal of Immunology Research
- Vol. 2020 (1) , 7235742
Open AccessWest Nile Virus Vaccine Design by T Cell Epitope Selection: In Silico Analysis of Conservation, Functional Cross‐Reactivity with the Human Genome, and Population Coverage
West Nile Virus (WNV) causes a debilitating and life‐threatening neurological disease in humans. Since its emergence in Africa 50 years ago, new strains of WNV and an expanding geographical distribution have increased public health concerns. There are no licensed therapeutics against WNV, limiting effective infection control. Vaccines represent the most efficacious and efficient medical intervention known. Epitope‐based vaccines against WNV remain significantly underexploited. Here, we use a selection protocol to identify a set of conserved prevalidated immunogenic T cell epitopes comprising a putative WNV vaccine. Experimentally validated immunogenic WNV epitopes and WNV sequences were retrieved from the IEDB and West Nile Virus Variation Database. Clustering and multiple sequence alignment identified a smaller subset of representative sequences. Protein variability analysis identified evolutionarily conserved sequences, which were used to select a diverse set of immunogenic candidate T cell epitopes. Cross‐reactivity and human leukocyte antigen‐binding affinities were assessed to eliminate unsuitable epitope candidates. Population protection coverage (PPC) quantified individual epitopes and epitope combinations against the world population. 3 CD8+ T cell epitopes (ITYTDVLRY, TLARGFPFV, and SYHDRRWCF) and 1 CD4+ epitope (VTVNPFVSVATANAKVLI) were selected as a putative WNV vaccine, with an estimated PPC of 97.14%.
- Open Access
- 10 December 2019
- Published by Springer Nature in BMC Bioinformatics
- Vol. 20 (S6) , 1-11
Computational assembly of a human Cytomegalovirus vaccine upon experimental epitope legacy
Background: Human Cytomegalovirus (HCMV) is a ubiquitous herpesvirus affecting approximately 90% of the world population. HCMV causes disease in immunologically naive and immunosuppressed patients. The prevention, diagnosis and therapy of HCMV infection are thus crucial to public health. The availability of effective prophylactic and therapeutic treatments remain a significant challenge and no vaccine is currently available. Here, we sought to define an epitope-based vaccine against HCMV, eliciting B and T cell responses, from experimentally defined HCMV-specific epitopes. Results: We selected 398 and 790 experimentally validated HCMV-specific B and T cell epitopes, respectively, from available epitope resources and apply a knowledge-based approach in combination with immunoinformatic predictions to ensemble a universal vaccine against HCMV. The T cell component consists of 6 CD8 and 6 CD4 T cell epitopes that are conserved among HCMV strains. All CD8 T cell epitopes were reported to induce cytotoxic activity, are derived from early expressed genes and are predicted to provide population protection coverage over 97%. The CD4 T cell epitopes are derived from HCMV structural proteins and provide a population protection coverage over 92%. The B cell component consists of just 3 B cell epitopes from the ectodomain of glycoproteins L and H that are highly flexible and exposed to the solvent. Conclusions: We have defined a multiantigenic epitope vaccine ensemble against the HCMV that should elicit T and B cell responses in the entire population. Importantly, although we arrived to this epitope ensemble with the help of computational predictions, the actual epitopes are not predicted but are known to be immunogenic.
- 10 December 2019
- Published by Springer Nature in BMC Bioinformatics
- Vol. 20 (S6) , 1-11
Open AccessComputational assembly of a human Cytomegalovirus vaccine upon experimental epitope legacy
Background: Human Cytomegalovirus (HCMV) is a ubiquitous herpesvirus affecting approximately 90% of the world population. HCMV causes disease in immunologically naive and immunosuppressed patients. The prevention, diagnosis and therapy of HCMV infection are thus crucial to public health. The availability of effective prophylactic and therapeutic treatments remain a significant challenge and no vaccine is currently available. Here, we sought to define an epitope-based vaccine against HCMV, eliciting B and T cell responses, from experimentally defined HCMV-specific epitopes. Results: We selected 398 and 790 experimentally validated HCMV-specific B and T cell epitopes, respectively, from available epitope resources and apply a knowledge-based approach in combination with immunoinformatic predictions to ensemble a universal vaccine against HCMV. The T cell component consists of 6 CD8 and 6 CD4 T cell epitopes that are conserved among HCMV strains. All CD8 T cell epitopes were reported to induce cytotoxic activity, are derived from early expressed genes and are predicted to provide population protection coverage over 97%. The CD4 T cell epitopes are derived from HCMV structural proteins and provide a population protection coverage over 92%. The B cell component consists of just 3 B cell epitopes from the ectodomain of glycoproteins L and H that are highly flexible and exposed to the solvent. Conclusions: We have defined a multiantigenic epitope vaccine ensemble against the HCMV that should elicit T and B cell responses in the entire population. Importantly, although we arrived to this epitope ensemble with the help of computational predictions, the actual epitopes are not predicted but are known to be immunogenic.
- Open Access
- 15 July 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-2
Peptide-Based Immunotherapeutics and Vaccines 2017
- 15 July 2018
- Published by Wiley in Journal of Immunology Research
- Vol. 2018, 1-2
Open AccessPeptide-Based Immunotherapeutics and Vaccines 2017
- Open Access
- 21 June 2018
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 93 (1) , 21-28
Selection‐based design of in silico dengue epitope ensemble vaccines
Dengue virus affects approximately 130 countries. Twenty‐five percentage of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal dengue haemorrhagic fever or dengue shock syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target dengue, we used an innovative immunoinformatics protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly conserved epitopes with experimentally verified immunogenicity. From 1597 CD4+ and MHC II epitopes, six MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY and WAYHGSYEV) and nine MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ and WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49%.
- 21 June 2018
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 93 (1) , 21-28
Open AccessSelection‐based design of in silico dengue epitope ensemble vaccines
Dengue virus affects approximately 130 countries. Twenty‐five percentage of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal dengue haemorrhagic fever or dengue shock syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target dengue, we used an innovative immunoinformatics protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly conserved epitopes with experimentally verified immunogenicity. From 1597 CD4+ and MHC II epitopes, six MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY and WAYHGSYEV) and nine MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ and WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49%.
- Open Access
- 1 May 2018
- Published by Elsevier in Molecular Immunology
- Vol. 97, 56-62
In silico design of Mycobacterium tuberculosis epitope ensemble vaccines
- 1 May 2018
- Published by Elsevier in Molecular Immunology
- Vol. 97, 56-62
Open AccessIn silico design of Mycobacterium tuberculosis epitope ensemble vaccines
- Open Access
- 15 March 2018
- Published by Springer Nature in BMC Immunology
- Vol. 19 (1) , 1-9
In silico prediction of cancer immunogens: current state of the art
Cancer kills 8 million annually worldwide. Although survival rates in prevalent cancers continue to increase, many cancers have no effective treatment, prompting the search for new and improved protocols. Immunotherapy is a new and exciting addition to the anti-cancer arsenal. The successful and accurate identification of aberrant host proteins acting as antigens for vaccination and immunotherapy is a key aspiration for both experimental and computational research. Here we describe key elements of in silico prediction, including databases of cancer antigens and bleeding-edge methodology for their prediction. We also highlight the role dendritic cell vaccines can play and how they can act as delivery mechanisms for epitope ensemble vaccines. Immunoinformatics can help streamline the discovery and utility of Cancer Immunogens.
- 15 March 2018
- Published by Springer Nature in BMC Immunology
- Vol. 19 (1) , 1-9
Open AccessIn silico prediction of cancer immunogens: current state of the art
Cancer kills 8 million annually worldwide. Although survival rates in prevalent cancers continue to increase, many cancers have no effective treatment, prompting the search for new and improved protocols. Immunotherapy is a new and exciting addition to the anti-cancer arsenal. The successful and accurate identification of aberrant host proteins acting as antigens for vaccination and immunotherapy is a key aspiration for both experimental and computational research. Here we describe key elements of in silico prediction, including databases of cancer antigens and bleeding-edge methodology for their prediction. We also highlight the role dendritic cell vaccines can play and how they can act as delivery mechanisms for epitope ensemble vaccines. Immunoinformatics can help streamline the discovery and utility of Cancer Immunogens.
- 1 November 2017
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 78, 195-205
In silico design of knowledge-based Plasmodium falciparum epitope ensemble vaccines
- 1 November 2017
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 78, 195-205
In silico design of knowledge-based Plasmodium falciparum epitope ensemble vaccines
- Open Access
- 1 October 2017
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 77, 130-136
Scrutinizing human MHC polymorphism: Supertype analysis using Poisson-Boltzmann electrostatics and clustering
- 1 October 2017
- Published by Elsevier in Journal of Molecular Graphics and Modelling
- Vol. 77, 130-136
Open AccessScrutinizing human MHC polymorphism: Supertype analysis using Poisson-Boltzmann electrostatics and clustering
- Open Access
- 1 October 2017
- Published by Elsevier in Journal of Theoretical Biology
- Vol. 430, 109-116
Protein lipograms
- 1 October 2017
- Published by Elsevier in Journal of Theoretical Biology
- Vol. 430, 109-116
Open AccessProtein lipograms
- Open Access
- 31 July 2017
- Published by Biomedical Informatics in Bioinformation
- Vol. 13 (07) , 220-223
Designing Epitope Ensemble Vaccines against TB by Selection: Prioritizing Antigens using Predicted Immunogenicity.
Tuberculosis (TB) is a global health burden, and a major cause of mortality and morbidity in West Africa. Here, we select key conserved pathogen epitopes of proven immunogenicity to form a potential TB epitope ensemble vaccine. We compared two vaccine formulations: one comprising class I epitopes from the 13 most prevalent class I epitope-bearing antigens and class II epitopes deriving from the 20 most prevalent class II epitope-bearing antigens and another consisting of epitopes derived solely from 5 antigens identified as the most immunogenic by VaxiJen. In the prevalence analysis, 279 class I and 561 class II epitopes were collected and a subset selected using our published methodology, yielding 32 conserved epitopes. Combining 9 conserved epitopes gave a putative vaccine with predicted population coverage (PPC) over 95%. This consists of ISSGVFLLK, AVAGAAILV, WYYQSGLSI, YQSGLSIVM, MPVGGQSSF, QSSFYSDWY, WDINTPAFEWYYQSGLSIVM, DAPLITNPGGLLEQAVAVEE and NQAVTPAARALPLTSLTSAA. 5 immunogenic antigens VaxiJen-identified yielded 187 epitopes, which we again analyzed using published protocol. This identified 11 conserved epitopes. From this set the highest PPC value (<85%) was obtained by combining: GQQYQAMSAQAAAFH, DDIKATYDKGILTVSVAVSE and AVAGAAILV. We conclude that prioritizing epitope selection using predicted immunogenicity alone is likely to be unduly restrictive and is currently not an optimal or advisable strategy in the design of epitope ensemble vaccines.
- 31 July 2017
- Published by Biomedical Informatics in Bioinformation
- Vol. 13 (07) , 220-223
Open AccessDesigning Epitope Ensemble Vaccines against TB by Selection: Prioritizing Antigens using Predicted Immunogenicity.
Tuberculosis (TB) is a global health burden, and a major cause of mortality and morbidity in West Africa. Here, we select key conserved pathogen epitopes of proven immunogenicity to form a potential TB epitope ensemble vaccine. We compared two vaccine formulations: one comprising class I epitopes from the 13 most prevalent class I epitope-bearing antigens and class II epitopes deriving from the 20 most prevalent class II epitope-bearing antigens and another consisting of epitopes derived solely from 5 antigens identified as the most immunogenic by VaxiJen. In the prevalence analysis, 279 class I and 561 class II epitopes were collected and a subset selected using our published methodology, yielding 32 conserved epitopes. Combining 9 conserved epitopes gave a putative vaccine with predicted population coverage (PPC) over 95%. This consists of ISSGVFLLK, AVAGAAILV, WYYQSGLSI, YQSGLSIVM, MPVGGQSSF, QSSFYSDWY, WDINTPAFEWYYQSGLSIVM, DAPLITNPGGLLEQAVAVEE and NQAVTPAARALPLTSLTSAA. 5 immunogenic antigens VaxiJen-identified yielded 187 epitopes, which we again analyzed using published protocol. This identified 11 conserved epitopes. From this set the highest PPC value (<85%) was obtained by combining: GQQYQAMSAQAAAFH, DDIKATYDKGILTVSVAVSE and AVAGAAILV. We conclude that prioritizing epitope selection using predicted immunogenicity alone is likely to be unduly restrictive and is currently not an optimal or advisable strategy in the design of epitope ensemble vaccines.